Do analysts recommend ACU or CERS?

Cerus has a consensus target price of $5.25, indicating a potential upside of 111.27%. Given Cerus' higher possible upside, analysts plainly believe Cerus is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Cerus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better earnings and valuation, ACU or CERS?

Acme United has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acme United $211.60M 1.11 $17.79M $2.38 25.88 Cerus $206.13M 2.43 -$15.63M -$0.03 N/A

Is ACU or CERS more profitable?

Acme United has a net margin of 10.25% compared to Cerus' net margin of -3.06%. Acme United's return on equity of 9.70% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Acme United 10.25% 9.70% 6.10% Cerus -3.06% -10.19% -3.14%

Does the media prefer ACU or CERS?

In the previous week, Acme United had 2 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Acme United and 3 mentions for Cerus. Acme United's average media sentiment score of 0.95 beat Cerus' score of 0.75 indicating that Acme United is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acme United 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ACU or SMTI?

Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 0.00%. Given Sanara MedTech's higher possible upside, analysts plainly believe Sanara MedTech is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has stronger earnings & valuation, ACU or SMTI?

Acme United has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acme United $211.60M 1.11 $17.79M $2.38 25.88 Sanara MedTech $103.12M 3.12 -$37.56M -$3.59 N/A

Does the media refer more to ACU or SMTI?

In the previous week, Acme United had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Acme United and 2 mentions for Sanara MedTech. Acme United's average media sentiment score of 0.95 beat Sanara MedTech's score of 0.90 indicating that Acme United is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acme United 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ACU or RXST?

RxSight has a consensus target price of $8.37, suggesting a potential upside of 41.47%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 RxSight 3 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.91

Which has stronger valuation and earnings, ACU or RXST?

Acme United has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acme United $211.60M 1.11 $17.79M $2.38 25.88 RxSight $134.48M 1.83 -$38.94M -$1.13 N/A

Is ACU or RXST more profitable?

Acme United has a net margin of 10.25% compared to RxSight's net margin of -36.80%. Acme United's return on equity of 9.70% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Acme United 10.25% 9.70% 6.10% RxSight -36.80% -17.35% -14.70%

Does the media refer more to ACU or RXST?

In the previous week, Acme United had 3 more articles in the media than RxSight. MarketBeat recorded 5 mentions for Acme United and 2 mentions for RxSight. Acme United's average media sentiment score of 0.95 beat RxSight's score of 0.63 indicating that Acme United is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acme United 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EMBC or ACU?

Embecta currently has a consensus price target of $11.00, indicating a potential upside of 120.66%. Given Embecta's higher probable upside, equities research analysts plainly believe Embecta is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has stronger valuation and earnings, EMBC or ACU?

Embecta has higher revenue and earnings than Acme United. Embecta is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.26 $95.40M $1.48 3.37 Acme United $211.60M 1.11 $17.79M $2.38 25.88

Is EMBC or ACU more profitable?

Acme United has a net margin of 10.25% compared to Embecta's net margin of 8.59%. Acme United's return on equity of 9.70% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% Acme United 10.25% 9.70% 6.10%

Does the media prefer EMBC or ACU?

In the previous week, Embecta and Embecta both had 5 articles in the media. Acme United's average media sentiment score of 0.95 beat Embecta's score of 0.53 indicating that Acme United is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acme United 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ACU or OSUR?

OraSure Technologies has a consensus target price of $3.00, indicating a potential downside of 6.98%. Given OraSure Technologies' higher probable upside, analysts plainly believe OraSure Technologies is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 OraSure Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor ACU or OSUR?

In the previous week, Acme United had 4 more articles in the media than OraSure Technologies. MarketBeat recorded 5 mentions for Acme United and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.44 beat Acme United's score of 0.95 indicating that OraSure Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acme United 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OraSure Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Acme United (ACU) Competitors

$61.29 -0.55 (-0.90%)

As of 11:39 AM Eastern

Compare

ACU vs. CERS, SMTI, RXST, EMBC, and OSUR

Should you buy Acme United stock or one of its competitors? Acme United's main competitors and comparable companies include Cerus (CERS), Sanara MedTech (SMTI), RxSight (RXST), Embecta (EMBC), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Acme United compare to Cerus?

Acme United (NYSE:ACU) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Acme United has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Cerus has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Acme United has a net margin of 10.25% compared to Cerus' net margin of -3.06%. Acme United's return on equity of 9.70% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acme United	10.25%	9.70%	6.10%
Cerus	-3.06%	-10.19%	-3.14%

In the previous week, Acme United had 2 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Acme United and 3 mentions for Cerus. Acme United's average media sentiment score of 0.95 beat Cerus' score of 0.75 indicating that Acme United is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acme United	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.1% of Acme United shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 29.5% of Acme United shares are held by insiders. Comparatively, 5.3% of Cerus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Acme United has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acme United	$211.60M	1.11	$17.79M	$2.38	25.88
Cerus	$206.13M	2.43	-$15.63M	-$0.03	N/A

Cerus has a consensus target price of $5.25, indicating a potential upside of 111.27%. Given Cerus' higher possible upside, analysts plainly believe Cerus is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Acme United beats Cerus on 12 of the 17 factors compared between the two stocks.

How does Acme United compare to Sanara MedTech?

Acme United (NYSE:ACU) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

62.1% of Acme United shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 29.5% of Acme United shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Acme United has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

In the previous week, Acme United had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Acme United and 2 mentions for Sanara MedTech. Acme United's average media sentiment score of 0.95 beat Sanara MedTech's score of 0.90 indicating that Acme United is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acme United	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acme United has a net margin of 10.25% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Acme United's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acme United	10.25%	9.70%	6.10%
Sanara MedTech	-29.15%	29.72%	2.84%

Acme United has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acme United	$211.60M	1.11	$17.79M	$2.38	25.88
Sanara MedTech	$103.12M	3.12	-$37.56M	-$3.59	N/A

Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 0.00%. Given Sanara MedTech's higher possible upside, analysts plainly believe Sanara MedTech is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Acme United beats Sanara MedTech on 11 of the 16 factors compared between the two stocks.

How does Acme United compare to RxSight?

Acme United (NYSE:ACU) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

RxSight has a consensus target price of $8.37, suggesting a potential upside of 41.47%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
RxSight	3 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.91

Acme United has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acme United	$211.60M	1.11	$17.79M	$2.38	25.88
RxSight	$134.48M	1.83	-$38.94M	-$1.13	N/A

62.1% of Acme United shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 29.5% of Acme United shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Acme United had 3 more articles in the media than RxSight. MarketBeat recorded 5 mentions for Acme United and 2 mentions for RxSight. Acme United's average media sentiment score of 0.95 beat RxSight's score of 0.63 indicating that Acme United is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acme United	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acme United has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, RxSight has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Acme United has a net margin of 10.25% compared to RxSight's net margin of -36.80%. Acme United's return on equity of 9.70% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acme United	10.25%	9.70%	6.10%
RxSight	-36.80%	-17.35%	-14.70%

Summary

Acme United beats RxSight on 12 of the 17 factors compared between the two stocks.

How does Acme United compare to Embecta?

Embecta (NASDAQ:EMBC) and Acme United (NYSE:ACU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Acme United has a net margin of 10.25% compared to Embecta's net margin of 8.59%. Acme United's return on equity of 9.70% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Acme United	10.25%	9.70%	6.10%

Embecta currently has a consensus price target of $11.00, indicating a potential upside of 120.66%. Given Embecta's higher probable upside, equities research analysts plainly believe Embecta is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Embecta has higher revenue and earnings than Acme United. Embecta is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.26	$95.40M	$1.48	3.37
Acme United	$211.60M	1.11	$17.79M	$2.38	25.88

93.8% of Embecta shares are held by institutional investors. Comparatively, 62.1% of Acme United shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 29.5% of Acme United shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Embecta pays an annual dividend of $0.04 per share and has a dividend yield of 0.8%. Acme United pays an annual dividend of $0.64 per share and has a dividend yield of 1.0%. Embecta pays out 2.7% of its earnings in the form of a dividend. Acme United pays out 26.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Acme United has increased its dividend for 20 consecutive years. Acme United is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Embecta has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Acme United has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

In the previous week, Embecta and Embecta both had 5 articles in the media. Acme United's average media sentiment score of 0.95 beat Embecta's score of 0.53 indicating that Acme United is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acme United	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Acme United beats Embecta on 11 of the 18 factors compared between the two stocks.

How does Acme United compare to OraSure Technologies?

Acme United (NYSE:ACU) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Acme United had 4 more articles in the media than OraSure Technologies. MarketBeat recorded 5 mentions for Acme United and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.44 beat Acme United's score of 0.95 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acme United	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OraSure Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acme United has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

Acme United has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acme United	$211.60M	1.11	$17.79M	$2.38	25.88
OraSure Technologies	$115.02M	1.93	-$68.73M	-$0.69	N/A

62.1% of Acme United shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 29.5% of Acme United shares are held by insiders. Comparatively, 4.7% of OraSure Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Acme United has a net margin of 10.25% compared to OraSure Technologies' net margin of -43.70%. Acme United's return on equity of 9.70% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acme United	10.25%	9.70%	6.10%
OraSure Technologies	-43.70%	-19.09%	-16.26%

OraSure Technologies has a consensus target price of $3.00, indicating a potential downside of 6.98%. Given OraSure Technologies' higher probable upside, analysts plainly believe OraSure Technologies is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Acme United beats OraSure Technologies on 11 of the 16 factors compared between the two stocks.

Get Acme United News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACU vs. The Competition

Export

Metric	Acme United	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$234.64M	$5.44B	$7.13B	$23.21B
Dividend Yield	1.01%	1.78%	2.55%	3.76%
P/E Ratio	12.59	24.82	273.75	28.62
Price / Sales	1.11	73.10	674.23	19.75
Price / Cash	10.02	32.78	77.55	34.36
Price / Book	2.26	5.96	10.48	4.73
Net Income	$17.79M	$150.94M	$3.49B	$1.07B
7 Day Performance	-2.48%	-2.34%	-2.32%	-1.90%
1 Month Performance	8.87%	-2.56%	0.81%	-2.44%
1 Year Performance	47.26%	8.79%	21.29%	11.10%

Acme United Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACU Acme United	1.2274 of 5 stars	$61.29 -0.9%	N/A	+44.8%	$235.45M	$211.60M	12.64	650
CERS Cerus	2.0236 of 5 stars	$2.61 -1.1%	$5.25 +101.1%	+94.6%	$532.03M	$206.13M	N/A	290	Positive News
SMTI Sanara MedTech	1.2409 of 5 stars	$34.79 -0.3%	$35.00 +0.6%	+1.9%	$320.48M	$103.12M	N/A	60
RXST RxSight	2.3375 of 5 stars	$6.99 -4.6%	$8.37 +19.7%	-35.3%	$304.88M	$134.48M	N/A	220	Positive News Analyst Forecast
EMBC Embecta	4.0126 of 5 stars	$5.25 +2.1%	$11.00 +109.5%	-66.4%	$291.23M	$1.08B	3.55	1,850	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ACU) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acme United (ACU) Competitors